Skip to main content
. 2017 Jul 20;158(10):3212–3234. doi: 10.1210/en.2017-00468

Figure 4.

Figure 4.

Indicators of enhancer activation are specifically enriched at NRFEs in response to hormone. To facilitate the presentation of data derived from multiple datasets in a single figure, each data point represents the log of the proportion of peaks that contain the genomic feature in the presence of hormone relative to vehicle conditions at B4 (Gro-seq), D1000 (RNAPII), or L4 (p300, FoxA1, DNase hypersensitivity) peak selection criteria. Thus, data points above zero represent individual datasets that show increased presence of the genomic feature at those sites in response to hormone. All null event counts were set to unity to avoid zero divisors. In these analyses, we are trying to determine if there is a general consensus among datasets from various studies on the “parity” of the ratio under consideration, that is, above/below 1 (i.e., ± logarithm). In particular, the magnitude that the logarithm differs from zero in an individual dataset is just “strength of opinion” with regard to our interest in the general trend of the overall parity of the family of results. (a) The proportion Gro-seq reads that contain a 0- to 3-nt variant ERE (and remaining peaks) in the presence of E2 relative to vehicle conditions at B4 peak selection criteria. (b) The proportion Gro-seq reads that contain a 0- to 3-nt variant HRE (and remaining peaks) in the presence of DHT or dex relative to vehicle conditions at B4 peak selection criteria. (c) The proportion of RNAPII ChIP-seq peaks that contain a 0- to 3-nt variant ERE (and remaining peaks) in the presence of E2 relative to vehicle conditions at D1000 peak selection criteria. (d) The proportion of RNAPII ChIP-seq peaks that contain a 0- to 3-nt variant HRE (and remaining peaks) in the presence of cort, dex, or pred relative to vehicle conditions at D1000 peak selection criteria. (e) The proportion of p300 ChIP-seq peaks that contain a 0- to 3-nt variant ERE (and remaining peaks) in the presence of E2 relative to vehicle conditions at L4 peak selection criteria. (f) The proportion of p300 ChIP-seq peaks that contain a 0- to 3-nt variant HRE (and remaining peaks) in the presence of dex, T, P4, or R5020 relative to vehicle conditions at L4 peak selection criteria. (g) The proportion of FoxA1 ChIP-seq peaks that contain a 0- to 3-nt variant ERE (and remaining peaks) in the presence of E2 relative to vehicle conditions at L4 peak selection criteria. (h) The proportion of FoxA1 ChIP-seq peaks that contain a 0- to 3-nt variant HRE (and remaining peaks) in the presence of dex, T, or R1881 relative to vehicle conditions at L4 peak selection criteria. (i) The proportion of DNase hypersensitive sites that contain a 0- to 3-nt variant ERE (and remaining peaks) in the presence of E2 relative to vehicle conditions at L4 peak selection criteria. (j) The proportion of DNase hypersensitive sites that contain a 0- to 3-nt variant HRE (and remaining peaks) in the presence of cort, dex, or T relative to vehicle conditions at L4 peak selection criteria. See also Supplemental Tables 3:1, 3:3, 3:5, 3:12, 3:14, 3:16, 3:18, 3:20, 3:24, and 3:26 (16.9MB, xlsx) .